PFIZER INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.
- Conditions
- Premature BirthSafety13-valent Pneumococcal VaccineImmunization
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT01193335
- Locations
- ๐ต๐ฑ
NZOZ "HIPOKRATES-II" Sp. z o.o., Krakow, Poland
๐ต๐ฑSzpital im. Sw. Jadwigi Slaskiej, Oddzial Pediatryczny, Trzebnica, Poland
๐ต๐ฑSpecjalistyczny ZOZ nad Matka i Dzieckiem, Poznan, Poland
Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)
- Conditions
- Depression - Major Depressive Disorder
- Interventions
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2012-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT01190514
- Locations
- ๐ง๐ช
Pfizer Investigational Site, Bruxelles, Belgium
Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
- Conditions
- Anti- VGF InhibitorDiabetic Macular EdemaDiabetic Retinopathy
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT01189461
- Locations
- ๐ช๐ธ
Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
๐ธ๐ชOgonkliniken, Centrallasarettet, Vasteras, Sweden
๐ฌ๐งKings College Hospital, London, United Kingdom
The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP)
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT01189487
- Locations
- ๐ฏ๐ต
Tosei General Hospital, Seto-shi, Aichi-ken, Japan
๐ฏ๐ตNagata Hospital, Yanagawa, Fukuoka, Japan
๐ฏ๐ตUniversity of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT01189500
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Miami, Florida, United States
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
- Conditions
- Cytochrome P-450 CYP2D6CYP3A4 Protein, HumanPharmacokinetics
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2011-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT01188668
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Miami, Florida, United States
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 89
- Registration Number
- NCT01188655
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
- Conditions
- AspergillosisNeuroaspergillosisInvasive Pulmonary Aspergillosis
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01188759
Multiple Dose Healthy Volunteer Study of PF-03715455.
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2011-01-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 36
- Registration Number
- NCT01186757
- Locations
- ๐ธ๐ฌ
Pfizer Investigational Site, Singapore, Singapore
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 666
- Registration Number
- NCT01186744
- Locations
- ๐บ๐ธ
Center for Dermatology Clinical Research, Inc., Fremont, California, United States
๐บ๐ธDermatology Specialists, Inc., Oceanside, California, United States
๐บ๐ธAmeriderm Research, Ormond Beach, Florida, United States